suicide

Cerecor halfway through $32M Series B, developing “Special K”-like med for severe depression

Baltimore-based Cerecor has a fast-tracked, fast-acting drug called CER-301 that treats those with severe major depressive disorder and suicidal tendencies. And it works a little like ketamine, the anesthetic-turned-illicit party drug-turned-psychiatric therapy du jour. The company just raised a $16 million tranche in a $32 million Series B round to fund ongoing Phase 2 trials for the medication. It also plans to use […]